ADMA Biologics to Report Third Quarter 2020 Financial Results and Business Highlights on November 5, 2020
ADMA Biologics announced a live conference call on November 5, 2020, at 4:30 p.m. ET, to discuss its Q3 2020 financial results and business highlights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics announced a live conference call on November 5, 2020, at 4:30 p.m. ET, to discuss its Q3 2020 financial results and business highlights. The call will be accessible via phone and an audio webcast, with an archived version available two hours post-event. ADMA specializes in manufacturing and marketing plasma-derived biologics, including ASCENIV™, BIVIGAM®, and NABI-HB®, approved by the FDA for treating immunodeficient patients. More information can be found on their website.
Positive
- ADMA operates FDA-approved manufacturing for plasma-derived biologics.
- The company has a dedicated conference call to discuss positive Q3 financial results.
Negative
- None.
Details
News Market Reaction – ADMA
The recorded move for ADMA in the trading session of this news was -1.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call and audio webcast on Thursday, November 5, 2020 at 4:30 p.m. ET, to discuss its financial results and business highlights for the third quarter ended September 30, 2020.
To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 8185674. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabiologics.com
INVESTOR RELATIONS CONTACT:
Sam Martin
Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.